

Supporting Information

Chlorinated cobalt alkyne complexes derived from acetylsalicylic acid as new specific antitumor agents

*Victoria Obermoser^{†‡}, Daniel Baecker^{†‡}, Carina Schuster[†], Valentin Braun[†], Brigitte
Kircher^{§‡}, Ronald Gust^{†*}*

[†] Department of Pharmaceutical Chemistry, Institute of Pharmacy, Center for Molecular
Biosciences Innsbruck, University of Innsbruck, CCB – Centrum for Chemistry and
Biomedicine, Innrain 80-82, 6020 Innsbruck, Austria

[§] Immunobiology and Stem Cell Laboratory, Department of Internal Medicine V
(Hematology and Oncology), Innsbruck Medical University, Anichstrasse 35, 6020
Innsbruck, Austria

[‡] Tyrolean Cancer Research Institute, Innrain 66, 6020 Innsbruck, Austria

[‡] these authors contributed equally to the publication

* corresponding author: Ronald Gust, e-mail address: Ronald.Gust@uibk.ac.at, phone: +43-
512-507-58200

Table of Contents

Synthesis and characterization of intermediate products	S3
Table S1: Inhibition of COX-1/2	S6
Table S2: Graphite furnace time-temperature program for Co analysis by HR CS AAS	S7
Supporting Figure 1: Proliferation of HT-29 cells	S8
Supporting Figure 2: Proliferation of MDA-MB-231 cells	S8
Supporting Figure 3: Proliferation of MCF-7 cells	S8
Supporting Figure 4: Caspase-3/7 induction (HT-29)	S9
Supporting Figure 5: Caspase-3/7 induction (MCF-7)	S9
Supporting Figure 6: Caspase-3/7 induction (MDA-MB-231)	S10
Table S3: Solvent gradient for stability analysis with HPLC	S11
Supporting Figure 7: Stability of 3-Cl-ASS	S12
Supporting Figure 8: Stability of 4-Cl-ASS	S14
Supporting Figure 9: Stability of 5-Cl-ASS	S16
Supporting Figure 10: Stability of 6-Cl-ASS	S18
Supporting Figure 11: Stability of 3-Cl-ASS propargyl ester	S20
Supporting Figure 12: Stability of 4-Cl-ASS propargyl ester	S22
Supporting Figure 13: Stability of 5-Cl-ASS propargyl ester	S24
Supporting Figure 14: Stability of 6-Cl-ASS propargyl ester	S26
Supporting Figure 15: ¹ H-NMR spectrum of 3-Cl-Co-ASS	S28
Supporting Figure 16: ¹ H-NMR spectrum of 4-Cl-Co-ASS	S29
Supporting Figure 17: ¹ H-NMR spectrum of 5-Cl-Co-ASS	S30
Supporting Figure 18: ¹ H-NMR spectrum of 6-Cl-Co-ASS	S31
Supporting Figure 19: HPLC chromatogram of 3-Cl-Co-ASS	S32
Supporting Figure 20: HPLC chromatogram of 4-Cl-Co-ASS	S33
Supporting Figure 21: HPLC chromatogram of 5-Cl-Co-ASS	S34
Supporting Figure 22: HPLC chromatogram of 6-Cl-Co-ASS	S35
Supporting Figure 23: HR-MS spectrum of 3-Cl-Co-ASS	S36
Supporting Figure 24: HR-MS spectrum of 4-Cl-Co-ASS	S37
Supporting Figure 25: HR-MS spectrum of 5-Cl-Co-ASS	S38
Supporting Figure 26: HR-MS spectrum of 6-Cl-Co-ASS	S39

Synthesis and characterization of intermediate products

6-Chlorosalicylic acid

From 4.0 g 2-chloro-6-fluorobenzoic acid (22.9 mmol), 3.7 g NaOH (91.7 mmol) and 45 ml anhydrous DMSO as solvent (12 h, 130 °C). After cooling to room temperature, the reaction mixture was diluted with 100 ml water and acidified with 1M HCl (pH 1). Water phase was extracted four times with 100 mL diethyl ether. Collected ether phases were washed with water and saturated NaCl solution and dried over NaSO₄. Diethyl ether was removed under reduced pressure. Purification: recrystallization from toluene; white solid; yield: 2.34 g (13.56 mmol, 59%); mp 122 °C.

¹H-NMR (200 MHz, CDCl₃): δ 7.37 (dd, ³J = 8.1 Hz, 1H, ArH-4), 7.02 (dd, ³J = 8.0 Hz, ⁴J = 0.8 Hz, 1H, ArH), 6.96 (dd, ³J = 8.0 Hz, ⁴J = 0.8 Hz, 1H, ArH); IR (ν cm⁻¹): 3100-2300 br (OH), 1630 s (C=O), 1590 s, 1564 s (C=C), 1223 s, 1192 s (C-O).

General procedure for the synthesis of chloroacetylsalicylic acids

1.0 g of chlorosalicylic acid (5.8 mmol) was dissolved in 20 ml of THF and added dropwise under cooling to a mixture of 20 ml of THF, 58 mmol acetic anhydride and 11.6 mmol of TEA. The mixture was stirred at room temperature until reaction was completed. 80 ml water was added and the reaction mixture was acidified with 1M HCl, then extracted three times with 50 ml of diethyl ether. Collected ether phases were washed with water and saturated NaCl solution and removed under reduced pressure. If necessary, product was purified with column chromatography prior to recrystallization. The product was recrystallized from toluene or a toluene-petroleum mixture.

3-Chloroacetylsalicylic acid (3-Cl-ASS)

Reaction time: 22.5 h; purification: recrystallization from petroleum/toluene (2:1); white solid; yield: 0.94 g (4.38 mmol, 76%); mp 122 °C.

¹H-NMR (200 MHz, CDCl₃): δ 8.02 (dd, ³J = 8.0 Hz, ⁴J = 1.8 Hz, 1H, ArH-6), 7.70 (dd, ³J = 8.4 Hz, ⁴J = 1.8 Hz, 1H, ArH-4), 7.31 (dd, ³J = 7.8 Hz, 1H, ArH-5), 2.40 (s, 3H, CH₃); IR (ν cm⁻¹): 3100-2400 br (OH), 1774 s, 1686 s (C=O), 1592 m, 1568 w (C=C), 1366 m (δ CH₃), 1274 m, 1181 s (C-O).

4-Chloroacetylsalicylic acid (4-Cl-ASS)

Reaction time: 19 h; purification: recrystallization from petroleum/toluene (2:1); white solid; yield: 1.06 g (4.94 mmol, 85%); mp 142 °C.

¹H-NMR (200 MHz, CDCl₃): δ 8.06 (d, ³J = 8.6 Hz, 1H, ArH-6), 7.34 (dd, ³J = 8.6 Hz, ⁴J = 1.8 Hz, 1H, ArH-5), 7.17 (d, ⁴J = 1.8 Hz, 1H, ArH-3), 2.34 (s, 3H, CH₃); IR (ν cm⁻¹): 3100-2400 br (OH), 1759 s, 1684 s (C=O), 1594 m (C=C), 1366 m (δ CH₃), 1278 s, 1188 s (C-O).

5-Chloroacetylsalicylic acid (5-Cl-ASS)

Reaction time: 3 h; purification: recrystallization from toluene; white solid; yield: 0.84 g (3.91 mmol, 68%); mp 142 °C.

¹H-NMR (200 MHz, CDCl₃): δ 8.09 (d, ⁴J = 2.4 Hz, 1H, ArH-6), 7.58 (dd, ³J = 8.4 Hz, ⁴J = 2.4 Hz, 1H, ArH-4), 7.10 (d, ³J = 8.4 Hz, 1H, ArH-3), 2.34 (s, 3H, CH₃); IR (ν cm⁻¹): 3100-2400 br (OH), 1751 s, 1688 s (C=O), 1600 m, 1562 m (C=C), 1364 m (δ CH₃), 1303 s, 1193 s, 1102 s (C-O).

6-Chloroacetylsalicylic acid (6-Cl-ASS)

Reaction time: 20 h; purification: column chromatography using ethyl acetate/petroleum/glacial acetic acid (8:6:0.5), recrystallization from petroleum/toluene (2:1); white solid; yield: 0.92 g (4.29 mmol, 74%); mp 121 °C.

¹H-NMR (200 MHz, CDCl₃): δ 7.43 (dd, ³J = 8.0 Hz, 1H, ArH-4), 7.36 (dd, ³J = 8.0 Hz, ⁴J = 1.8 Hz, 1H, ArH-5), 7.12 (dd, ³J = 7.6 Hz, ⁴J = 1.8 Hz, 1H, ArH-3), 2.31 (s, 3H, CH₃); IR (ν cm⁻¹): 3100-2700 br (OH), 1771 s, 1716 s, 1651 m (C=O), 1596 s, 1576 m (C=C), 1365 m (δ CH₃), 1258 s, 1179 s (C-O).

General procedure for the synthesis of chloroacetylsalicylic acid propargyl ester

The Cl-ASS derivative was dissolved in 10 ml anhydrous DCM. 0.2 equivalent DMAP and 1.1 equivalent propargyl alcohol were added under stirring, followed by the addition of 1.1 equivalent DCC under ice cooling. After 5 min of vigorous stirring, the ice bath was removed and reaction mixture was stirred at room temperature for 2 – 3 h. A white precipitate was built (dicyclohexylurea, DCU), which was removed by filtration. The basic solvent was evaporated, the residue was dissolved in DCM and if necessary filtrated again. DCM phase was washed twice with 0.5M HCl and saturated NaHCO₃ solution, dried over NaSO₄ and evaporated under reduced pressure. As resulting yellowish oil is a mixture of the salicylic acid ester and the acetylsalicylic acid ester, acetylation was carried out again.

General procedure for the (re-)acetylation of chlorosalicylic acid propargyl ester

The (re-)acetylation was conducted analogously to the synthesis of chloroacetylsalicylic acids. Although, the starting material was a mixture of salicylic acid and acetylsalicylic acid ester, calculation of reaction mixture was calculated based on the pure chlorosalicylic acid ester. Workup was performed as described in the *General procedure for the synthesis of chloroacetylsalicylic acids*, except for the acidification before extraction which was not necessary. After removal of the solvent under reduced pressure, possibly generated DCU crystals were removed by filtration after dissolution in toluene. Toluene was removed under reduced pressure, a yellowish solid crystallizes, which was resuspended in petroleum. The product was collected on a frit and washed with petroleum.

2-Acetoxy-3-chlorobenzoic acid prop-2-ynyl ester (3-Cl-ASS propargyl ester)

From 0.70 g 3-chloroacetylsalicylic acid (3.26 mmol), 0.21 ml propargyl alcohol (3.59 mmol), 0.74 g DCC (3.59 mmol) and 0.08 g DMAP (0.65 mmol). White crystalline solid; yield: 0.59 g (2.34 mmol, 67%); mp 61 °C.

¹H-NMR (200 MHz, CDCl₃): δ 8.01 (d, ³J = 8.8 Hz, 1H, ArH-6), 7.31 (dd, ³J = 8.4 Hz, ⁴J = 2.2 Hz, 1H, ArH-5), 7.15 (d, ³J = 2.2 Hz, 1H, ArH-3), 4.87 (d, ⁴J = 2.6 Hz, 2H, CH₂), 2.54 (t, ⁴J = 2.4 Hz, 1H, CH), 2.37 (s, 3H, CH₃); IR (ν cm⁻¹): 3249 m (C≡C-H), 3081 w (Aryl-C-H), 2944 w, 2855 w (C-H), 2129 w (C≡C), 1761 s, 1718 s (C=O), 1600 s, 1568 m (C=C), 1372 m (δ -CH₃), 1262 s, 1202 s, 1099 s (C-O).

2-Acetoxy-4-chlorobenzoic acid prop-2-ynyl ester (4-Cl-ASS propargyl ester)

From 0.70 g 4-chloroacetylsalicylic acid (3.26 mmol), 0.21 ml propargyl alcohol (3.59 mmol), 0.74 g DCC (3.59 mmol) and 0.08 g DMAP (0.65 mmol). White crystalline solid; yield: 0.50 g (1.98 mmol, 51%); mp 49 °C.

¹H-NMR (200 MHz, CDCl₃): δ 8.01 (d, ³J = 8.8 Hz, 1H, ArH-6), 7.31 (dd, ³J = 8.4 Hz, ⁴J = 2.2 Hz, 1H, ArH-5), 7.15 (d, ³J = 2.2 Hz, 1H, ArH-3), 4.87 (d, ⁴J = 2.6 Hz, 2H, CH₂), 2.54 (t, ⁴J = 2.4 Hz, 1H, CH), 2.37 (s, 3H, CH₃); IR (ν cm⁻¹): 3249 m (C≡C-H), 3081 w (Aryl-C-H), 2944 w, 2855 w (C-H), 2129 w (C≡C), 1761 s, 1718 s (C=O), 1600 s, 1568 m (C=C), 1372 m (δ -CH₃), 1262 s, 1202 s, 1099 s (C-O).

2-Acetoxy-5-chlorobenzoic acid prop-2-ynyl ester (5-Cl-ASS propargyl ester)

From 0.80 g 5-chloroacetylsalicylic acid (3.73 mmol), 0.24 ml propargyl alcohol (4.10 mmol), 0.85 g DCC (4.10 mmol) and 0.09 g DMAP (0.65 mmol). White crystalline solid; yield: 0.60 g (2.37 mmol, 64%); mp 55 °C.

¹H-NMR (200 MHz, CDCl₃): δ 8.03 (d, ⁴J = 3.0 Hz, 1H, ArH-6), 7.54 (dd, ³J = 8.8 Hz, ⁴J = 3.0 Hz, 1H, ArH-4), 7.07 (d, ³J = 8.8 Hz, 1H, ArH-3), 4.88 (d, ⁴J = 2.4 Hz, 2H, CH₂), 2.55 (t, ⁴J = 2.5 Hz, 1H, CH), 2.37 (s, 3H, CH₃); IR (ν cm⁻¹): 3246 m (C≡C-H), 3116 w, 3068 w (Aryl-C-H), 2931 w, 2850 w (C-H), 2128 w (C≡C), 1749 s, 1720 s (C=O), 1601 w, 1574 w (C=C), 1370 m (δ -CH₃), 1202 s, 1081 s (C-O).

2-Acetoxy-6-chlorobenzoic acid prop-2-ynyl ester (6-Cl-ASS propargyl ester)

From 0.47 g 6-chloroacetylsalicylic acid (2.19 mmol), 0.14 ml propargyl alcohol (2.41 mmol), 0.50 g DCC (2.41 mmol) and 0.05 g DMAP (0.44 mmol). White crystalline solid; yield: 0.23 g (0.91 mmol, 35%); mp 68 °C.

¹H-NMR (200 MHz, CDCl₃): δ 7.40 (dd, ³J = 7.9 Hz, 1H, ArH-4), 7.32 (dd, ³J = 8.1 Hz, ⁴J = 1.5 Hz, 1H, ArH-3), 7.11 (dd, ³J = 8.0 Hz, ⁴J = 1.6 Hz, 1H, ArH-5), 4.93 (d, ⁴J = 2.6 Hz, 2H, CH₂), 2.55 (t, ⁴J = 2.5 Hz, 1H, CH), 2.30 (s, 3H, CH₃); IR (ν cm⁻¹): 3252 m (C≡C-H), 3081 w (Aryl-C-H), 2960 w, 2833 w, 2850 w (C-H), 2125 w (C≡C), 1768 s, 1746 s (C=O), 1595 m, 1576 m (C=C), 1369 m (δ -CH₃), 1269 s, 1182 s (C-O).


Table S1: Inhibition of COX-1/2

compound	concentration [μ M]	COX-1 [%]	COX-2 [%]	PGE2 [%]
ASS	10 μ M	28.8 ± 3.7	0.6 ± 2.8	2.3 ± 2.7
ASS	100 μ M	73.3 ± 8.7	59.4 ± 8.7	25.4 ± 4.3
3-Cl-ASS	100 μ M	27.0 ± 6.1	29.5 ± 3.5	n. t.
4-Cl-ASS	100 μ M	60.2 ± 6.2	55.0 ± 2.7	n. t.
5-Cl-ASS	100 μ M	56.4 ± 5.7	42.8 ± 0.4	n. t.
6-Cl-ASS	100 μ M	30.0 ± 2.9	30.6 ± 3.2	n. t.
ASS-Propargyl	100 μ M	25.4 ± 4.4	34.5 ± 4.2	n. t.
propargyl-3-Cl-ASS	100 μ M	32.5 ± 1.9	52.2 ± 5.7	n. t.
propargyl-4-Cl-ASS	100 μ M	24.0 ± 7.7	47.2 ± 5.3	n. t.
propargyl-5-Cl-ASS	100 μ M	34.6 ± 0.5	52.0 ± 8.2	n. t.
propargyl-6-Cl-ASS	100 μ M	37.3 ± 7.1	47.4 ± 6.0	n. t.
Co-ASS	10 μ M	82.7 ± 3.2	78.5 ± 6.1	57.5 ± 3.0
3-Cl-Co-ASS	10 μ M	24.9 ± 2.6	71.4 ± 8.3	37.7 ± 6.7
4-Cl-Co-ASS	10 μ M	22.9 ± 1.7	69.9 ± 2.7	48.5 ± 6.8
5-Cl-Co-ASS	10 μ M	25.0 ± 1.0	64.0 ± 7.5	41.9 ± 4.2
6-Cl-Co-ASS	10 μ M	24.4 ± 3.0	70.5 ± 3.5	18.3 ± 1.9


Table S2: Graphite furnace time-temperature program for Co analysis by HR CS AAS

step	operation	temperature	heating rate	hold time	argon flow
1	drying	80 °C	10 °C/s	10 s	maximal
2	drying	100 °C	10 °C/s	25 s	maximal
3	drying	120 °C	15 °C/s	10 s	maximal
4	pyrolysis	1100 °C	200 °C/s	20 s	maximal
5	auto-zero	1100 °C	0 °C/s	5 s	stop
6	atomization	2300 °C	1500 °C/s	5 s	stop
7	cleaning	2600 °C	500 °C/s	4 s	maximal


Supporting Figure 1: Proliferation of HT-29 cells




Supporting Figure 2: Proliferation of MDA-MB-231 cells




Supporting Figure 3: Proliferation of MCF-7 cells



Supporting Figure 4: Caspase-3/7 induction (HT-29)



Supporting Figure 5: Caspase-3/7 induction (MCF-7)



Supporting Figure 6: *Caspase-3/7 induction (MDA-MB-231)*





Table S3: Solvent gradient for stability analysis with HPLC


compound	Time [min]	ACN [%]	AcOH (1%) [%]
3-Cl-ASS, 4-Cl-ASS, 5-Cl-ASS, 3-Cl-ASS propargyl ester, 4-Cl-ASS propargyl ester, 5-Cl-ASS propargyl ester	0 – 2	40	60
	2 – 6	40 – 60	60 – 40
	6 – 11	60 – 100	40 – 0
	11 – 11.5	100	0
	11.5 – 15	40	60
6-Cl-ASS, 6-Cl-ASS propargyl ester	0 – 2	20	80
	2 – 6	20 – 40	80 – 60
	6 – 11	40 – 90	60 – 10
	11 – 11.5	90 – 20	10 – 80
	11.5 – 15	20	80

Supporting Figure 7: Stability of 3-Cl-ASS


0 Stunden




8 Stunden




24 Stunden




48 Stunden




72 Stunden




96 Stunden




168 Stunden




Supporting Figure 8: Stability of 4-Cl-ASS




72 Stunden




96 Stunden




Supporting Figure 9: Stability of 5-Cl-ASS



72 Stunden




96 Stunden




Supporting Figure 10: Stability of 6-Cl-ASS

0 Stunden




8 Stunden



24 Stunden




48 Stunden




72 Stunden



96 Stunden




168 Stunden




Supporting Figure 11: Stability of 3-Cl-ASS propargyl ester


0 Stunden




8 Stunden




24 Stunden




48 Stunden




72 Stunden



96 Stunden




168 Stunden




Supporting Figure 12: Stability of 4-Cl-ASS propargyl ester


0 Stunden




8 Stunden




24 Stunden




48 Stunden



72 Stunden




96 Stunden




Supporting Figure 13: Stability of 5-Cl-ASS propargyl ester

5-Chloroacetylsalicylsäurepropargylester


0 Stunden




8 Stunden




24 Stunden




48 Stunden




72 Stunden




96 Stunden




Supporting Figure 14: Stability of 6-Cl-ASS propargyl ester




72 Stunden




96 Stunden




Supporting Figure 15: ^1H -NMR spectrum of 3-Cl-Co-ASS




Supporting Figure 16: ^1H -NMR spectrum of 4-Cl-Co-ASS




Supporting Figure 17: ^1H -NMR spectrum of 5-Cl-Co-ASS



Supporting Figure 18: ^1H -NMR spectrum of 6-Cl-Co-ASS




Supporting Figure 19: HPLC chromatogram of 3-Cl-Co-ASS




Wavelength	Retention Time	Area	Height	Concentration
348	4.559	2607625	159228	99.803
	6.230	5135	325	0.196

Supporting Figure 20: HPLC chromatogram of 4-Cl-Co-ASS




Wavelength	Retention Time	Area	Height	Concentration
348	5.349	3090301	170777	95.576
	7.777	34471	1448	1.066
	8.586	108547	4058	3.357

Supporting Figure 21: HPLC chromatogram of 5-Cl-Co-ASS




Wavelength	Retention Time	Area	Height	Concentration
348	5.221	2812359	160382	99.638
	7.174	10215	545	0.361

Supporting Figure 22: HPLC chromatogram of 6-Cl-Co-ASS




Wavelength	Retention Time	Area	Height	Concentration
348	4.329	2578456	169291	100.0

Supporting Figure 23: *HR-MS spectrum of 3-Cl-Co-ASS*




Supporting Figure 24: HR-MS spectrum of 4-Cl-Co-ASS



Supporting Figure 25: *HR-MS spectrum of 5-Cl-Co-ASS*

206-01-16 5Cl-CoASS_2 #1-74 RT: 0.01-0.53 AV: 74 NL: 7.05E6
T: FTMS + p ESI Full ms [150.00-2000.00]



Supporting Figure 26: *HR-MS spectrum of 6-Cl-Co-ASS*

